Orthocell Limited
(ASX:OCC) has entered into a research collaboration with Johnson and Johnson for its stem cell products.
The product, Ortho-ATI, is a non-surgical approach that treats resistant tendons and ligament injuries.
The companies will conduct a collaborative study in the first quarter of 2017 and conduct a trial with leading orthopaedic surgeons.
Ortho-ATI is available in Australian and New Zealand.
Orthocell posted a net loss $3.8 million at 30 June 2016.
